EA200701879A1 - Замещённые производные оксадиазаспиро [5.5] ундеканона и их применение в качестве антагонистов нейрокинина - Google Patents

Замещённые производные оксадиазаспиро [5.5] ундеканона и их применение в качестве антагонистов нейрокинина

Info

Publication number
EA200701879A1
EA200701879A1 EA200701879A EA200701879A EA200701879A1 EA 200701879 A1 EA200701879 A1 EA 200701879A1 EA 200701879 A EA200701879 A EA 200701879A EA 200701879 A EA200701879 A EA 200701879A EA 200701879 A1 EA200701879 A1 EA 200701879A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antagonistic activity
oxadiazaspiro
neurokinin
addition salts
combined
Prior art date
Application number
EA200701879A
Other languages
English (en)
Other versions
EA012421B1 (ru
Inventor
Франс Эдуард Янссенс
Софи Купа
Алан Филипп Понселе
Брюно Схунтьес
Original Assignee
Янссен Фармацевтика Н. В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н. В. filed Critical Янссен Фармацевтика Н. В.
Publication of EA200701879A1 publication Critical patent/EA200701879A1/ru
Publication of EA012421B1 publication Critical patent/EA012421B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Данное изобретение касается замещенных производных оксадиазаспиро[5.5]ундеканона, имеющих антагонистическую активность в отношении нейрокинина, в частности NK-антагонистическую активность, NK-антагонистическую активность, объединенную NK/NK-антагонистическую активность и объединенную NK/NK/NK-антагонистическую активность, их получения, композиций, их содержащих, и их применения в качестве лекарственного средства, в частности, для лечения и/или профилактики шизофрении, рвоты, тревожности и депрессии, синдрома раздраженного кишечника (IBS), нарушений циркадного ритма, преэклампсии, ноцицепции, боли, в частности висцеральной и невропатической боли, панкреатита, нейрогенного воспаления, астмы, хронического обструктивного заболевания легких (ХОЗЛ) и расстройств мочеиспускания, таких как недержание мочи. Соединения в соответствии с данным изобретением могут быть представлены общей формулой (I) и включают также их фармацевтически приемлемые кислотно-аддитивные соли или основно-аддитивные соли, их стереохимически изомерные формы, форму N-оксида и пролекарства, где все заместители являются такими, как определено в п.1.
EA200701879A 2005-03-03 2006-03-03 Замещённые производные оксадиазаспиро[5.5]ундеканона и их применение в качестве антагонистов нейрокинина EA012421B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05101657 2005-03-03
PCT/EP2006/060419 WO2006094934A1 (en) 2005-03-03 2006-03-03 Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists

Publications (2)

Publication Number Publication Date
EA200701879A1 true EA200701879A1 (ru) 2008-02-28
EA012421B1 EA012421B1 (ru) 2009-10-30

Family

ID=34938877

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701879A EA012421B1 (ru) 2005-03-03 2006-03-03 Замещённые производные оксадиазаспиро[5.5]ундеканона и их применение в качестве антагонистов нейрокинина

Country Status (15)

Country Link
US (1) US8138334B2 (ru)
EP (1) EP1874783B1 (ru)
JP (1) JP5094422B2 (ru)
KR (1) KR101355064B1 (ru)
CN (1) CN101133064B (ru)
AT (1) ATE469159T1 (ru)
AU (1) AU2006222061B2 (ru)
BR (1) BRPI0608074A2 (ru)
CA (1) CA2598530C (ru)
DE (1) DE602006014531D1 (ru)
EA (1) EA012421B1 (ru)
ES (1) ES2346147T3 (ru)
MX (1) MX2007010728A (ru)
NZ (1) NZ556629A (ru)
WO (1) WO2006094934A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
EP3915560A1 (en) 2014-06-25 2021-12-01 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
KR101579688B1 (ko) 2014-07-08 2015-12-24 재단법인 전남생물산업진흥원 좁쌀풀 추출물을 유효성분으로 함유하는 과민성 대장증후군에 의한 내장 통증 억제예방 또는 치료용 약학 조성물
EP3704271B1 (en) 2017-11-02 2026-01-28 California Institute of Technology Neurokinin antagonists and uses thereof
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
EP4181928A4 (en) * 2020-07-18 2024-07-03 Hoth Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING PNEUMONIA

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403593A (en) 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
TW429256B (en) 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
TW382017B (en) 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
EP1023065A1 (en) 1997-08-29 2000-08-02 Dsm N.V. Granules free of excipients
US6482829B2 (en) * 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
DK1308439T3 (da) * 2000-08-10 2009-01-12 Mitsubishi Tanabe Pharma Corp Prolinderivater og anvendelse af disse som lægemidler
EP1390372B1 (en) * 2001-05-14 2008-07-16 F. Hoffmann-La Roche Ag 1-oxa-3,9-diaza-spiro'5,5]undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor
KR100974901B1 (ko) 2001-12-28 2010-08-10 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
MY141736A (en) * 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
KR20060006098A (ko) * 2003-06-10 2006-01-18 얀센 파마슈티카 엔.브이. 오피오이드 진통제와 배합된 치환된1,4-디-피페리딘-4-일-피페라진 유도체 및 오피오이드계치료와 관련된 통증 및 부작용 치료용으로 이들의 용도
KR100863854B1 (ko) * 2004-02-10 2008-10-15 에프. 호프만-라 로슈 아게 케모카인 ｃｃｒ5 수용체 조절제

Also Published As

Publication number Publication date
US20100292228A1 (en) 2010-11-18
EP1874783A1 (en) 2008-01-09
CA2598530A1 (en) 2006-09-14
KR101355064B1 (ko) 2014-01-24
ES2346147T3 (es) 2010-10-11
EA012421B1 (ru) 2009-10-30
JP2008531659A (ja) 2008-08-14
US8138334B2 (en) 2012-03-20
NZ556629A (en) 2010-04-30
DE602006014531D1 (de) 2010-07-08
CN101133064A (zh) 2008-02-27
AU2006222061A1 (en) 2006-09-14
BRPI0608074A2 (pt) 2009-11-03
CA2598530C (en) 2014-12-16
AU2006222061B2 (en) 2011-04-28
JP5094422B2 (ja) 2012-12-12
MX2007010728A (es) 2007-10-12
CN101133064B (zh) 2011-02-23
WO2006094934A8 (en) 2006-12-07
WO2006094934A1 (en) 2006-09-14
ATE469159T1 (de) 2010-06-15
EP1874783B1 (en) 2010-05-26
KR20070113224A (ko) 2007-11-28

Similar Documents

Publication Publication Date Title
TW200604198A (en) Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists
WO2010018113A3 (en) Bi-aryl aminotetralines
EA200601880A1 (ru) Замещенные производные 4-алкил- и 4-алканоилпиперидина и их применение в качестве антагонистов нейрокининов
WO2010018109A3 (en) Substituted aminotetralines
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
IL190411A (en) Amidated pyrimidine compounds as pgds inhibitors
WO2008080844A9 (en) Azaspiro derivatives
SG155932A1 (en) Chemical compounds
MY142090A (en) Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists
WO2007056219A3 (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
WO2010018112A3 (en) Monoaryl aminotetralines
MX2009005507A (es) Derivados de espiro-piperidina.
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
SI1957484T1 (sl) Antagonisti glukagonskega receptorja, priprava in terapevtske uporabe
MX2009006454A (es) Derivados de espiro-piperidina.
BRPI0608074A2 (pt) derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo
MX2009005541A (es) Indoles que actuan como antagonistas del receptor v1a.
MX2009005544A (es) Indoles.
MX2009005504A (es) Derivados de espiro piperidina como antagonistas del receptor via.
MX2009006446A (es) Derivados de espiro-piperidina.
EA200701898A1 (ru) Производные диаза-спиро-[4.4]-нонана в качестве антагонистов нейрокинина (nk1)
EA200501040A1 (ru) Замещенные производные 1-пиперидин-3-ил-4-пиперидин-4-илпиперазина и их применение в качестве антагонистов нейрокинина
DE602005022558D1 (de) Mikroemulsionsformulierungen mit bestimmten substanz p antagonisten
MY145168A (en) Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists
TH103173B (th) อนุพันธ์ของไดอะซา-สปิโร-[5.5]-อันเดคเคนและการใช้ของมันเป็นแอนทาโกนิสท์ของนิวโรไคนิน

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU